BEIJING, Feb. 6 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical company in the People's Republic of China ("PRC"), today announced that it has achieved significant milestones in the development of isosorbide mononitrate sustained release tablet, a highly effective drug for the prevention and treatment of angina.
Based on extensive clinical trials, isosorbide mononitrate sustained release tablet has shown optimistic results in a study of 1,350 patients with angina who received the drug for over six months. Lotus plans to release the details of the study, and expects to launch the drug pending the approval from SFDA in 2009. Approximately 0.4 to 0.8 million people in China suffer from angina and that figure is anticipated to grow over the coming years due to increases in the aging population. Lotus estimates it will achieve a 10% to 20% market share within two years of launching the drug and a 30% market share within three years.
The drug dilates the blood vessels and lowers the blood pressure. AstraZeneca sells the drug under the trade name Imdur. The components of the drug include matrix tablets, isosorbide mononitrate, and hydroxypropylmethylcellulose (HPMC). Both components are available at low cost and the tablet is easy to manufacture in large scale, which may result in high profit margins for Lotus.
"We have achieved significant milestones for the development of the isosorbide mononitrate sustained release tablet in both pre-clinical trials and manufacturing capabilities," said Dr. Zhongyi Liu, Chairman, CEO and President of Lotus Pharmaceuticals, Inc. "We look forward to introducing this drug, which will diversify the portfolio of our major drugs."
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. ("Lotus") controls and operates Liangfang
Pharmaceutical, Ltd. ("Liangfang") and Enze Jiashi Pharmaceutical, Ltd.
|SOURCE Lotus Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved